deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT01280201

Pazopanib as Single Agent in Advanced NETs

A Phase II, Open Label, Uncontrolled and Multicenter Trial of Pazopanib Given as a Single Agent in Patients With Progressive Advanced/Metastatic Neuroendocrine Tumors (NET): a Search for Activity, Safety, and Predictive Biomarkers

Sponsor: Grupo Espanol de Tumores Neuroendocrinos

Conditions Advanced/Metastatic Neuroendocrine Tumors
Interventions Pazopanib
Updated 11 times since 2017 Last updated: May 15, 2019 Started: Jan 26, 2011 Primary completion: Apr 30, 2013 Completion: Mar 15, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01280201, this PHASE2 trial focuses on Advanced/Metastatic Neuroendocrine Tumors and remains completed. Sponsored by Grupo Espanol de Tumores Neuroendocrinos, it has been updated 11 times since 2011, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshotCompleted~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshotCompleted~Jun 2019 – ~Jan 2021 · 19 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotCompleted~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

11 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

▶ Show 6 earlier versions

  1. Dec 2021 — Dec 2022 [monthly]

    Completed PHASE2

  2. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE2

  3. Jun 2019 — Jan 2021 [monthly]

    Completed PHASE2

  4. Apr 2019 — Jun 2019 [monthly]

    Completed PHASE2

  5. Jun 2018 — Apr 2019 [monthly]

    Completed PHASE2

  6. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Grupo Espanol de Tumores Neuroendocrinos
Data source: Grupo Espanol de Tumores Neuroendocrinos

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations